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Background/Aims: The diagnosis of gastrointestinal stromal 
tumors (GIST) relies on the demonstration of KIT expression, 
but KIT expression is absent or reduced in approximately 
15% of GIST. Methods: Eighty-one GISTs were diagnosed 
between January 1998 and December 2007 at the Depart-
ment of Pathology at both Chungnam National University 
Hospital and Eulji University Hospital, Daejeon. Medical his-
tory, patient follow-up, and radiographic data were collected 
if available in the medical records. To determine diagnostic 
and prognostic markers for GISTs focused on PDGFRA mu-
tation and clinicopathologic features, we analyzed 81 GIST 
cases for KIT, PDGFRA, DOG1, and p16 expression and for 
mutation of PDGFRA genes. Results: Among 81 GIST cases, 
20 high risk cases (24.7%) were recurred or metastasized. 
Immunohistochemically, KIT was positive in 76 (93.8%), 
PDGFRA in 75 (92.7%), and DOG1 in 77 (95.1%). With a 
cutoff value of 50%, p16 expression was positive in 26 cases 
were positive (32.1%). A correlation between p16 expression 
or negative DOG1 expression and recurrence or metastasis 
was demonstrated (p<0.05). Four cases showed a missense 
mutation in exon 12 of PDGFRA gene, three of these were 
of epithelioid GISTs. Two cases showed a silent mutation in 
exon 18 of PDGFRA. Conclusions: These results indicate that 
the expression of DOG1 and PDGFRA is observed in a ma-
jority of GIST cases. Expression of p16 and negative DOG1 
expression is predictive for development of recurrence and/
or metastasis. Even though mutation of the PDGFRA gene is 
frequently seen in epithelioid GISTs, a clinicopathologic cor-
relation was not demonstrated. (Gut Liver 2011;5:171-180)
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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) originate from the 
interstitial cells of Cajal (ICC).
1,2 The observation that ICC can 
be immunohistochemically highlighted with an antibody to KIT 
(CD117) lead to the discovery that KIT is also strongly expressed 
in most GISTs.
1-3 Although approximately 95% of GISTs stain 
positive for KIT (CD117),
3,4 recent molecular studies have deter-
mined that some of these tumors are KIT negative.
4,5 
Approximately 80% to 85% of GISTs exhibit activating 
mutations of KIT tyrosine kinase. Some of these tumors have 
mutations in the KIT-related kinase gene PDGF receptor alpha 
(PDGFRA) in exons 18 (5.6%) or 12 (1.5%). The remainder of 
GISTs (12%) are wild type (WT) for both KIT and PDGFRA.
4 The 
responsiveness of GISTs to treatment using the kinase inhibitor 
imatinib varies, depending on the exonic location of the Kit or 
PDGFA mutation. Corless et al.
4 proposed a molecular-based 
classification of GIST. 
KIT-low/negative GISTs are a heterogeneous group com-
prised, in part, by tumors with PDGFRA mutations and, in part, 
by tumors with KIT mutations. The vast majority of PDGFRA-
mutant GISTs express little or no KIT, perhaps because down-
regulation of the wild-type KIT gene is advantageous.
6
Most GISTs are comprised of a fairly uniform population of 
spindle cells (70% of cases), but some are dominated by epitheli-
oid cells (20% of cases), and the remainder consists of a mixture 
of these two types.  Success in treating GISTs with imatinib has 
emphasized early diagnosis. Fibromatosis and leiomyosarcoma 
are perhaps the most common tumors misdiagnosed as GIST.
4,7
Recently, West et al.
8 identified DOG1 (TMEM16A) as a gene 
with a high level of GIST expression and developed a rabbit 
polyclonal antibody and an in situ hybridization probe that 
target DOG1 using gene expression profiling. A following study 
showed that mouse monoclonal antibodies against the DOG1 
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antibody are more sensitive and more specific than the anti-
CD117 reagent.
9
p16 is a tumor suppressor protein that inhibits cell cycling by 
arresting cells in G1 before entry into the S phase.
10 Loss of the 
p16 protein has been reported to be correlated with high-risk 
GIST and is a predictor of a poor clinical outcome in a variety 
of human tumors.
11-13 In contrast, an adverse effect of p16 ex-
pression on prognosis was recently described.
10,14 The prognostic 
significance of p16 gene alterations in GIST is still unknown.  
In this study, we evaluated the diagnostic and prognostic 
markers for GIST focused on PDGFRA mutations and clinico-
pathologic features.  
MATERIALS AND METHODS
Eighty-one GISTs were diagnosed between January 1998 and 
December 2007 at the Department of Pathology at both Chun-
gnam National University Hospital and Eulji University Hospital. 
The studies described here were performed with the approval of 
the Institutional Review Board at Chungnam National Univer-
sity School of Medicine. Medical history, patient follow-up, and 
radiographic data were collected, if available, from the medical 
records. 
1. Histologic evaluation
Hematoxylin and eosin (H&E)-stained sections were reviewed 
by two pathologists in each case. A diagnosis of GIST was made 
based on tumor location, morphology, and immunostaining for 
KIT. Five KIT-negative cases were accepted as GIST based on 
no histologic or immunophenotypic support for smooth muscle 
differentiation. Mitoses were counted in 50 consecutive high-
power fields (HPFs) from the most cellular and mitotically active 
area. According to tumor size and mitotic activity, GISTs was 
classified into very low risk, low risk, intermediate risk, and high 
risk categories according to Fletcher et al.
7 The cell type feature 
was classified as spindle, epithelioid, or mixed cell type (Fig. 1). 
2. Immunohistochemical study
Representative areas from 81 GISTs were selected for con-
struction of tissue microarrays using a 3 mm punch. Two 
punches per case were taken from 81 cases. Immunohistochemi-
cal analyses for p16, KIT, PDGFRA, and DOG1 were performed. 
Four micrometer sections were cut from the tissue microarray 
blocks and placed onto coated slides. Immunohistochemical 
staining was performed using a polyclonal anti-CD117 (KIT) 
antibody (dilution 1:300; Dako, Capinteria, CA, USA), PDGFRA 
Fig. 1. Gastrointestinal stromal tumors, high-grade. Spindle cell type (A, B: H&E stain, ×400) and epithelioid type (C, D: H&E stain, ×400).Jung SH, et al: DOG1, PDGFRA, and p16 Expression in GISTs  173
(dilution 1:250; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA), and p16 (dilution 1:80), and DOG1 (1:120). Immunohis-
tochemical staining was evaluated via estimation of 10 HPTs.
12 
A membranous and/or cytoplasmic staining pattern for KIT, 
PDGFRA, and DOG1 was considered positive. Nuclear staining 
with or without a cytoplasmic reaction for p16 was counted. 
Tissue cores were scored (on the basis of the percentage of posi-
tive tumor cells staining above the background) as negative 
(0%), weakly positive (<10%), moderately positive (10-50%) or 
diffusely positive (>50%). Scoring results were catagorized as ei-
ther negative (score of 0 or 1) or positive (score of 2 or 3).
10 For 
p16, we also analyzed a cutoff value of 50%.
14 
3. DNA extraction
Sixty tumor samples (25 intermediate risk tumors and 35 
high risk tumors) were taken from formalin fixed, paraffin 
embedded (FFPE) tissue samples. H&E-stained 4 μm sections 
were reviewed under a microscope and areas rich in tumor cells 
were marked. Corresponding areas on unstained sections were 
scraped from the slides using a scalpel blade. Tumor samples 
that contained as few non-neoplastic cells as possible (70-90% 
tumor cellularity) were collected. A total of 3 to 5 dissected 
10 μm sections were incubated at 55˚C for one day in 400 μL 
of DNA extraction buffer (0.25 μg/μL of proteinase K (Roche, 
Mannheim, Germany), 20 mM Tris/HCl, pH 8.3 mM MgCl2, 
100 mM KCl, 1% Tween-20, and 1% NP-40). The mixture was 
boiled for 10 minutes to inactivate the proteinase K, followed by 
phenol-chloroform extraction for purification, and then concen-
trated using ethanol precipitation.
4. PCR ampliﬁ  cation of the PDGFRA gene 
Polymerase chain reaction (PCR) primers were designed to 
amplify exons 12 and 18 of the PDGFRA gene.
15 PCR amplifica-
tion was performed in a total volume of 20 μL containing 500 
ng of template DNA, one unit of ExTaq polymerase (Takara, 
Shiga, Japan), 1.25 mM dNTP, 15 pmole of primers, and 2 μL of 
1 X reaction buffer. PCR cycles consisted of 5 minutes at 94˚C, 
followed by 35 cycles of 30 seconds at 94˚C, 30 seconds at 55˚C, 
and 30 seconds at 72˚C, followed by one cycle for 7 minutes at 
72˚C.
5. SSCP analysis, silver staining, and direct sequencing
Two μL of PCR product was mixed with 6 μL of sample load-
ing buffer containing 95% formide (deionized), 10 mM NaOH, 
0.25% Bromophenol blue, and 0.25% Xylene cyanol, denatured 
for 3 minutes at 100˚C, and quickly chilled on ice. The solution 
was then loaded onto 12% polyacrylamide gel containing 1 X 
sample buffer (33 mM Tris-sulfate, 7% Glycerol, pH 8.3), and 
electrophoresed at 250 V. After electrophoresis the gel was dis-
assembled from the glass plate, then stained using a Silver Stain 
Plus kit (Bio-Rad, Hercules, CA, USA), followed by air drying. 
Samples with abnormal bands were sequenced automatically 
using a Genetic analyzer (Applied Biosystems, Foster City, CA, 
USA). 
6. Statistical analysis
Statistical analysis was performed using SPSS software (PASW 
Statistics version 18.0; SPSS Inc., Chicago, IL, USA). Both age 
and tumor size among the risk groups were analyzed using the 
Kruskal-Wallis test.  Histologic parameters and recurrence were 
correlated with p16, DOG1, and KIT immunostaining results us-
ing a two-sided χ
2 test or Fisher’s exact test. A two-tailed value 
p<0.05 was considered to be statistically significant.
RESULTS 
1. Clinical presentation
Eighty-one patients (mean age, 58.7 years; SD, 13.5; male/
female ratio, 1:0.95; 39 men, 37 women) underwent surgical re-
section for GIST. Three GIST patients had additional malignant 
tumors (one stomach cancer, one breast cancer, and one chol-
angiocarcinoma). Among 81 GISTs, 44 cases (54.3%) occurred 
Table 1. Clinicopathologic Features of GISTs
Clinicopathologic features No. (%)
Localization of primary tumor
  Stomach 44 (54.3)
  Small intestine 23 (28.4)
  Colon 4 (4.9)
  Esophagus 2 (2.5)
  Others (EGIST) 8 (9.9)
Histologic pattern
  Spindle cell-like 62 (76.5)
  Epithelioid 10 (12.3)
  Mixed pattern 9 (11.1)
Risk of malignancy
  Very low risk 5 (6.2)
  Low risk 16 (19.8)
  Intermediate risk 25 (30.9)
  High risk 35 (43.2)
Immunohistochemistry
  c-Kit+ 76 (93.8)
  p16+ cutoff >10% 
        + cutoff >50%
36 (44.4)
26 (32.1)
  PDGFRA+ 75 (92.7)
  DOG1+ 77 (95.1)
Recurrence or metastasis   20 (24.7)
PDGFRA mutation (exon) 5
  Missense mutation (12-1) 4
  Silent mutation (18) 1
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in the stomach, 23 cases (28.4%) in the small intestine, 4 cases 
(4.9%) in the colon, 2 cases (2.5%) in the esophagus, and 8 cases 
(9.9%) in the extraintestinal location. A total of 20 (24.7%) high 
risk GIST patients were affected by tumor recurrence and/or 
metastases within a median time of 24.3 months (range, 3 to 84 
months) (Table 1). Among the high risk group, six patients were 
treated with imatinib in addition to surgery. Eight patients died 
of GIST. 
2. Histopathologic and immunohistochemical analyses
Sixty two GISTs (76.5%) were predominantly spindle cell 
type, 10 (12.3%) were epithelioid-like, and 9 tumors (11.1%) 
exhibited a mixed pattern. The tumors were classified into very 
low risk (5 cases, 6.2%), low risk (16 cases, 19.8%), intermediate 
risk (25 cases, 30.9%), and high risk categories (35 cases, 43.2%) 
(Table 1).
7 The tumor size ranged from 0.3 cm to 24 cm (mean 
of very low risk group was 1.1 cm; of low risk group was 4.3 
cm; of intermediate risk group was 6.6 cm; of high risk group 
was 11.7 cm). Immunohistochemically, c-kit was positive in 
76 (93.8%) of 81 GIST cases, PDGFRA in 75 cases (92.7%), and 
DOG1 in 77 cases (95.1%).  With a cutoff value of 10%, p16 ex-
pression was positive in 36 cases (44.4%) and with a cutoff val-
ue of 50%, 26 cases were positive (32.1%) (Table 1, Figs. 2 and 3). 
Among 5 c-kit negative cases, four were DOG+/PDGFRA+ and 
one was DOG+/PDGFRA- (Table 2). There were no correlations 
between p16, KIT, DOG1 or PDGFRA expression and the risk of 
malignancy (p>0.05) (Table 3). However, a correlation between 
p16 expression and recurrence and/or metastasis was demon-
strated (p<0.05). Negative DOG1 expression was correlated with 
recurrence and/or metastasis (p<0.05) (Table 4).
Fig. 2. Gastrointestinal stromal tumors of the small intestine, high-grade, spindle cell type (A, H&E stain, ×400), with liver metastasis within 24 
months (B, H&E stain, ×400). Nuclear expression of p16 (C, immunohistochemical stain for p16, ×400) and cell membrane/cytoplasmic staining of 
DOG1 (D, immunohistochemical stain for DOG1, ×400).
Table 2. DOG1 and PDGFRA Expression in Five KIT-Negative GISTs
GIST antibody
Very 
low risk
Low risk
Interme-
diate risk
High risk
DOG1+/PDGFRA+ 5 2 1 1
DOG1+/PDGFRA- 0 1 0 0
GISTs, gastrointestinal stromal tumors.Jung SH, et al: DOG1, PDGFRA, and p16 Expression in GISTs  175
Fig. 3. Gastrointestinal stromal tumors of the stomach, high-grade, spindle cell type (A, H&E stain, ×400), with liver metastasis within 34 months. 
Cytoplasmic expression of DOG1 (B, immunohistochemical stain for DOG1, ×400) and PDGFRA (C, immunohistochemical stain for PDGFRA, ×400).
Table 3. Clinicopathologic and Immunohistochemical Features of GISTs
  
Very low risk
(n=5)
Low risk
(n=16)
Intermediate risk
(n=25)
High risk
(n=35)
p-value
Age, Mean±SD, yr 54.2±12.4 64.5±9.6 58.7±12.4   55.8±11.7
Kruskall-Wallis test
0.1260
Tumor size, Mean±SD, cm 1.1±0.7   4.3±0.8 6.6±2.2 11.7±7.7 <0.0001*
p16 
  Cut off >10%  + 2 6 8 20
Chi-square test
0.2400
 -
  Cut off >50%  +
 -
3
1
4
10
5
11
17
6
19
15
14
21
0.5527
c-kit   + 5 13 24 34 0.1347
 - 0311
PDGFRA + 5 14 22 34 0.4185
 - 0231
DOG1 + 5 16 25 31 0.1368
 - 0004
Recurrence + 0 0 0 20 <0.0001*
 - 5 16 25 15
GISTs, gastrointestinal stromal tumors.
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3. PDGFRA mutations
Three cases showed a missense mutation in exon 12-1 of 
PDGFRA and one case showed a missense mutation in exon 
12-2 of PDGFRA. Three of four exon 12 mutated GISTs were 
epithelioid (Figs. 4 and 5). The remaining one was mixed cell 
type (Table 5). Two PDGFRA-mutated GISTs developed in the 
stomach, one was from the colon, and one was from the esoph-
agus. Among four exon 12 mutated GISTs, 3 were high risk and 
1 was intermediate risk. One epithelioid type also showed a si-
lent mutation in exon 12-1. One mixed cell type and one spin-
dle GIST also showed a silent mutation in exon 18 of PDGFRA. 
All PDGFRA-mutated GISTs were positive for KIT, PDGFRA, or 
DOG1 except one case. No significant clinicopathologic cor-
relation between PDGFRA expression and mutation was dem-
onstrated. There was no correlation between PDGFRA mutation 
and recurrence and/or metastasis. 
DISCUSSION
Most (~95%) GISTs show positive immunoreactivity for KIT 
protein expression.
3,4 However, recent studies have identified a 
small group of KIT-negative GISTs
4,5 with KIT or PDGFRA mu-
tations, which may be sensitive to imatinib therapy. These cases 
require special attention for diagnosis.
4,5 Diagnosis of a KIT-
negative GIST can be supported by immunostains for desmin 
and the S-100 protein, which exclude smooth muscle tumors 
and neural tumor like schwannomas.
16 
Molecular analysis of the KIT and PDGFRA genes is necessary 
Table 5. Clinicopathologic Characteristics of Patients with PDGFRA Gene Mutations
Case
no.
Age/
Sex
Site
Risk
group
Cell type
KIT
IHC
PDG-
FRA
IHC
DOG1
IHC
p16
IHC
PDGFRA mutation
Dis.status
(F/U mo) Exon 
Nucleotide 
change
Amino acid 
change
Mutation
10 52/M Esophagus High Epithelioid + + + - 12-2 TATˠAAT Tyrˠ
Asn (Y573N)
Missense 
  mutation
Recurrence (4)
Expire (7)
11 69/M Stomach High Spindle + + + - 18 GGAˠGGT Glyˠ
Gly (G829G)
Silent 
  mutation
NED (60)
14 63/F Stomach Intermediate Mixed + + + - 12-1 ATGˠAGG Metˠ
Arg (M578R)
Missense 
  mutation
NED (24)
18 GGAˠGGT Glyˠ
Gly (G829G)
Silent 
  mutation
28 60/M Stomach High Epithelioid + + + - 12-1 ATGˠAAG Metˠ
Lys (M578K)
Missense 
  mutation
Peritoneal
  seeding (37)
Expire (40)
36 40/M Colon High Epithelioid  + + - + 12-1 ATGˠAGG Metˠ
Arg (M578R)
Missense 
  mutation
Liver 
  metastasis (5)
12-1 GACˠGAT Aspˠ
Asp (577)
Silent 
  mutation
Expire (7)
F/U, follow-up.
Table 4. Pathologic and Immunohistochemical Features of GISTs with 
or without Recurrence or Metastases
Parameters
Recurred case 
(%)
(n=20)
No recurrence 
(%)
(n=61)
p-value
Histologic grade Chi-square test
  Very low risk
  Low risk
  0 (0)
  0 (0)
  5 (6.2)
16 (19.8)
<0.0001*
  Intermediate risk   0 (0) 25 (30.9)
  High risk 20 (24.7) 15 (18.5)
Fisher’s exact test
c-Kit       + 19 (23.5) 57 (70.4) 1.0000
-   1 (1.2)   4 (4.9)
PDGFRA    + 19 (23.5) 56 (69.1) 1.0000
-   1 (1.2)   5 (6.2)
p16 
  Cutoff >10%      + 13 (16.0) 23 (28.4)
 
0.0407*
  Cutoff >50%   
-
+
-
  7 (8.6)
12 (14.8)
  8 (9.8)
38 (46.9)
14 (17.3)
47 (58.0)
0.0047*
DOG1      + 16 (19.8) 61 (75.3)  0.0029*
-   4 (4.9)   0 (0)
GISTs, gastrointestinal stromal tumors.
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for accurate diagnosis of KIT-immunonegative GISTs, but prac-
tical application is difficult in the routine diagnostic process. 
Therefore, the diagnosis of GIST still depends on immunohisto-
chemical staining. Recent studies have reported that PDGFRA, 
protein kinase θ (PKCθ), and FLJ10261 (DOG1, discovered on 
GIST-1) expressions were detected in WT KIT GIST. Therefore, 
PDGFRA, PKCθ, and FLJ10261 can be used as diagnostic mark-
ers for GIST, especially in KIT negative cases.
17 
In this study, we found that PDGFRA, like KIT, was expressed 
Fig. 4. Demonstration of PDGFRA mutations (T deletion) in exon 12-2 (TATˠAAT, TyrˠAsn: Y573N, missense mutation) (A, normal; B, tumor). 
Epithelioid gastrointestinal stromal tumors of the esophagus, high-grade (C, H&E stain, ×400), showing strong PDGFRA expression (D, immuno-
histochemical stain for PDGFRA, ×400). This tumor recurred within 4 months following the operation (case no. 10).
in the majority (92.7%) of GISTs. Recently, the routine use of 
PDGFRA immunophenotyping has been reported to be a useful 
diagnostic tool, especially in KIT-negative cases, as it correctly 
predicts the presence of PDGFRA mutations.
18 KIT-negative 
GISTs were positive for PDGFRA and PDGRFA-negative GISTs 
were positive for KIT (CD117).
17,18 Therefore, both PDGFRA and 
KIT (CD117) can be used for diagnosis and differential diag-
nosis of GISTs. According to Zheng et al.,
17 PDGFRA protein 
expression cannot be used as a prognostic index. In our study, 
Fig. 5. Demonstration of a PDG-
FRA (TˠG) mutation in exon 12-1 
(ATGˠAGG, MetˠArg (M578R), 
missense mutation) (A, normal; B, 
tumor) (case no. 14).178  Gut and Liver, Vol. 5, No. 2, June 2011
PDGFRA protein expression showed no correlation with clino-
copathologic parameters in GIST patients.   
Another diagnostic marker has been developed for accurate 
diagnosis of GISTs. Recently, West et al.
8 characterized gene ex-
pression patterns in GISTs using a cDNA microarray and found 
that the gene FLJ10261 (DOG1, discovered on GIST 1), encoding 
a hypothetical protein, was specifically expressed in GISTs. A 
new mouse monoclonal antibody against DOG1 was reported 
to have a high sensitivity and specificity for GISTs.
9 With the 
use of DOG1.1, more than a third of KIT-negative GISTs can be 
classified using IHC.
19 DOG1.1 is an especially sensitive immu-
nohistochemical marker for GIST, and has potential for clinical 
use in the routine diagnosis of GIST.
9 DOG1 has been recently 
identified as a gene in the CCND1-EMS1 locus on human chro-
mosome 11q13, which is amplified in several cancers, includ-
ing head and neck, bladder, and breast.
20 Although DOG1 was 
found to be expressed in various tumors, the biological function 
and the overexpression mechanism in GIST are still unknown. 
West et al.
8 suggested two possible mechanisms. ICCs are immu-
noreactive for DOG1, as in KIT. This finding suggests the possi-
bility that the protein has a role in receptor kinase type III signal 
transduction pathways. On the other hand, DOG1 may be a 
fortuitous marker of the GIST phenotype with no direct connec-
tion to the KIT and PDGFRA signaling pathways.
12 DOG1 was 
highly expressed in KIT-and PDGFRA-mutant GISTs.
8,9 These 
results have important clinical value in identifying patients for 
imatinib therapy. Therefore, DOG1 may play a role in develop-
ment of GIST and may be an additional diagnostic marker and 
potential therapeutic target in GIST.  
There have been several studies indicating that DOG1 may be 
a new diagnostic marker for GIST, however, its prognostic im-
plication is still unknown. Espinosa et al.
9 reported that DOG1.1 
expression was not related to the type of mutation (KIT or PDG-
FRA), site, tumor size, tumor grade, or patient age. In our study, 
DOG1 was expressed in 95.1% of cases, and DOG1-negative 
GIST cases were significantly correlated with recurrence and/
or metastasis (p=0.0029). These findings indicate that DOG1 is 
a new diagnostic marker with potential to also be a prognostic 
marker.
GISTs are characterized by alterations in genes involved in 
cell cycle regulation. p16 (INK4A) is a tumor suppressor pro-
tein that inhibits cell cycling by arresting cells in G1 before 
entry into the S phase.
14 Although p16 has been extensively 
investigated in GISTs, there are still discrepancies regarding its 
prognostic value.
10 Herein, we studied immunohistochemical 
staining for p16 with >10% and >50% cutoff values to see if it 
can aid in clinical prognostic assessment in GISTs. In our study, 
patients expressing p16 were found to do worse than those not 
expressing p16. GISTs with p16 protein expression had a signif-
icantly higher recurrence rate and/or metastatic behavior (>10% 
cutoff value, p<0.0407; >50% cutoff value, p<0.0047). Two 
similar studies of the effect of p16 protein expression on prog-
nosis have recently reported that expression of p16 significantly 
correlates with a poor prognosis in GIST.
10,14 Schmieder et al.
14 
reported that in patients with high risk GIST, the immunohis-
tochemical expression of the p16 protein was highly predictive 
(p<0.05) for a poor prognosis (the development of recurrence). 
They suggested that, in addition, p16 expression might be an 
indicator for “very high risk GIST.” They analyzed prognoses 
with >10%, >20%, and >50% p16 expression cutoff values.     
Survival decreased significantly with a cutoff value >50%. 
In contrast to our results, loss of the p16 protein was corre-
lated with high risk GIST and poor clinical outcomes in several 
studies.
11-13 p16 gene alterations correlated significantly with 
loss of p16 protein expression. p16 protein loss can be caused 
by many mechanisms, as shown in other studies,
11-13 including 
loss of heterozygosity of chromosome 9p, methylation of the 
p16 gene promoter region, a loss-of-function mutation, or a 
submicroscopic small deletion of the CDKN2A gene locus.
11-13 
However, which pathophysiological role p16 plays in the onco-
genesis of GIST remains unknown and it might even change at 
different stages of tumorigenesis. Loss of p16 expression con-
tributes to malignancy and genetic alterations, and diminished 
p16 levels are common in human cancers.
21 However, expres-
sion of the p16 protein correlates with an unfavorable prognosis 
and a poor clinical outcome in GIST.
10,14 This implies that p16 
loss is not required for oncogenesis, and other mechanisms up-
setting cell-cycle control may be involved.
10
Although the predictive value of p16 in GIST has been de-
termined, the prognostic significance of p16 gene alterations 
in GIST is still under debate.
11-13,21 It is difficult to estimate the 
predictive value of p16 in GIST because different methods, dif-
ferent cutoff values, different follow-up durations, and different 
search variables have been used and the comparability between 
studies is limited. Each study used different positive values of 
p16 expression with different cutoff values.
10-14 In our study, we 
found that 44.4% of cases were positive for p16 immunostain-
ing with a cutoff value of 10%, and 32.1% were positive with 
a cutoff value of 50%. With a cutoff value of 10% the reported 
p16 immunostaining positivity in defined GIST was 42%,
14 and 
with a cutoff value of 50%
12 the reported positivity was 43%.
10 
KIT and PDGFRA genes encode KIT and PDGFRA, which 
belong to the type III transmembrane tyrosine kinase receptor 
family.
4 Mutation of KIT has been implicated as a major genetic 
event in the tumorigenesis of GISTs because most GISTs show 
a gain-of-function mutation in KIT.
1 Recently, the mutation 
of PDGFRA has been considered as another causative genetic 
event
6 as PDGFRA mutations were found in most GISTs lack-
ing a KIT mutation. Constitutional KIT gene mutations were 
observed in 75% to 80% of GISTs.
4,22,23 PDGFRA gene mutations 
are observed in up to 22.5% of cases.
22-26 PDGFRA mutations 
occur preferentially in exon 18 and rarely in exon 12.
23 PDG-
FRA-mutant tumors arise primarily in the stomach, mesentery, 
and omentum.
27,28 In this study, we found that PDGFRA muta-Jung SH, et al: DOG1, PDGFRA, and p16 Expression in GISTs  179
tions were identified in 5 (8.3%) of 60 cases (intermediate and 
high risk groups). These cases showed both KIT and PDGFRA 
expression. Four GISTs showed a missense mutation of exon 
12 (three cases for exon 12-1 and one case for exon 12-2), 
with two cases showing a silent mutation in exon 18. Muta-
tions involved codons 578 and 753. In four tumors (2125CˠA, 
n=2, or TˠA, n=2) missense mutations leading to substitution 
of lysine for asparagines (Y573N, M578R) were identified. No 
Y573N, M578K, or M578R mutant, which was identified in our 
study, was found in the literature. However, it has been reported 
that all exon 12 PDGFRA mutant GISTs were clustered between 
560 and 577 PDGFRA amino-acid residues, and that this re-
gion should be considered as a minor mutational “hot spot” for 
GIST.
27 A PDGFRA mutation in KIT negative GIST was not con-
firmed as a KIT gene mutation study was not performed in this 
study.
There is a large variation between the apparent frequencies of 
PDGFRA mutation in different studies. The frequency of PDG-
FRA mutations differs between 0-22.5%.
22-26 In other studies in 
Korea, PDGFRA gene mutations were observed in 3.1%
29 and 
13.6%
30 of cases. However, an exon 12 mutation was not found 
in other studies. Several factors, such as baseline characteristics 
of the enrolled population, different anatomical sites for enrolled 
GISTs, different diagnostic criteria, ethnic or racial factors, and 
technical problems, may have affected these results. We found a 
significant association between PDGFRA mutation and the epi-
thelioid/mixed phenotype. It has previously been observed that 
the vast majority of PDGFRA mutant GIST have been found to 
be associated with a gastric location and a predominantly epi-
thelioid morphology.
5,27-29 Several recent studies have proposed 
that the type and location of PDGFRA mutations in GIST can 
be used to predict the response to imatinib treatment. The most 
common PDGFRA mutation, D842V in exon 18, is resistant 
to imatinib.
6,25,27 In contrast, the substitution V561D in exon 
12 results in an isoform of PDGFRA that is highly sensitive to 
imatinib.
6,27 Lasota et al.
27 and Heinrich et al.
6 reported imatinib 
sensitivities for a deletion/substitution (SPDGHE566-571R) and 
an in-frame insertion mutation (ER561-562) in exon 12. In our 
study, four patients with PDGFRA exon 12 mutated GIST did 
not undergo imatinib treatment, so we could not determine the 
response to imatinib treatment.
Previous studies showed a tendency of a better prognosis for 
PDGFRA than for KIT mutated tumors.
26,27 In contrast, our study 
identified 3 cases of either a short survival or an unfavorable 
outcome associated with an exon 12 GIST mutation, all with an 
epithelioid morphology and a high grade malignancy. However, 
the number of PDGFRA-mutant GISTs reported in our study 
was relatively small, so an unfavorable prognosis for PDGFRA 
mutant GIST could not be confirmed.
In summary, expression of DOG1 and PDGFRA is observed 
in a majority of GISTs. Expression of p16 and negative DOG1 
expression is predictive for development of recurrence and/
or metastasis. Even though mutation of the PDGFRA gene is 
frequently seen in epithelioid GISTs, the significance of a clini-
copathologic correlation between PDGFRA expression and mu-
tation was not demonstrated. PDGFRA and the DOG1 immunos-
taining can be useful in diagnosis and differential diagnosis of 
GISTs. DOG1 has potential to be both a diagnostic marker and 
a prognostic marker. GISTs with p16 protein expression have 
a significantly higher recurrence rate; however, the prognostic 
significance in GIST is still unknown.
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